Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting

Stefania Bettelli; Raffaella Marcheselli; Samantha Pozzi; Luigi Marcheselli; Robel Papotti; Elisa Forti; M Christina Christina Cox; Arianna Di Napoli; Tamar Tadmor; Giovanna R Mansueto; Pellegrino Musto; Leonardo Flenghi; Martina Quintini; Sara Galimberti; Vittoria Lalinga; Valentina Donati; Antonino Maiorana; Aaron Polliack; Stefano Sacchi

doi:10.1016/j.leukres.2021.106552

Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting

Leuk Res. 2021 May:104:106552. doi: 10.1016/j.leukres.2021.106552. Epub 2021 Feb 27.

Authors

Stefania Bettelli¹, Raffaella Marcheselli², Samantha Pozzi³, Luigi Marcheselli², Robel Papotti⁴, Elisa Forti¹, M Christina Christina Cox⁵, Arianna Di Napoli⁶, Tamar Tadmor⁷, Giovanna R Mansueto⁸, Pellegrino Musto⁹, Leonardo Flenghi¹⁰, Martina Quintini¹⁰, Sara Galimberti¹¹, Vittoria Lalinga¹², Valentina Donati¹³, Antonino Maiorana³, Aaron Polliack¹⁴, Stefano Sacchi¹⁵

Affiliations

¹ SSD Patologia Molecolare e Medicina Predittiva, AOU Modena, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Italy.
² Fondazione Italiana Linfomi - Onlus, Modena, Italy.
³ Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Italy.
⁴ International PhD School in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.
⁵ Haematology Department, King's College Hospital NHS Trust and UOC Ematologia, AOU Sant'Andrea, Roma, Italy.
⁶ Anatomia Patologica, Ospedale Sant'Andrea, Roma, Italy.
⁷ Hematology, Bnai Zion Medical Center, Haifa, Israel.
⁸ IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
⁹ Aldo Moro University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOU Consorziale Policlinico, Bari, Italy.
¹⁰ Azienda Ospedaliera di Perugia, Department of Emergency and Organ Transplantation, Italy.
¹¹ Ematologia, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
¹² Anatomia Patologica, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
¹³ Anatomia Patologica, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
¹⁴ Hadassah- Hebrew University Medical Center Jerusalem, Israel.
¹⁵ Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Italy. Electronic address: stefano.sacchi@unimore.it.

PMID: 33689920
DOI: 10.1016/j.leukres.2021.106552

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Doxorubicin
Female
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / genetics
Lymphoma, Large B-Cell, Diffuse* / metabolism
Lymphoma, Large B-Cell, Diffuse* / mortality
Male
Middle Aged
Prednisone
Proto-Oncogene Proteins c-bcl-2* / genetics
Proto-Oncogene Proteins c-bcl-2* / metabolism
Proto-Oncogene Proteins c-myc / administration & dosage*
Proto-Oncogene Proteins c-myc / adverse effects
Proto-Oncogene Proteins c-myc / genetics
Proto-Oncogene Proteins c-myc / metabolism
Retrospective Studies
Rituximab
Vincristine

Substances

BCL2 protein, human
MYC protein, human
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-myc
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone